Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas.
A Phase II study of teniposide (VM26) in cutaneous T-cell lymphoma (CTCL) was performed in 15 patients affected by stage III, IV according to TNM (mycosis fungoides or Sézary syndrome). All patients were pretreated, and VM26 was administered at a dose of 100 mg/m2 weekly for at least 3 weeks. Objective responses were observed in 40% of the patients, with two complete responses lasting 26 and 46 months. The drug was well tolerated in elderly patients and deserves further evaluation either for inclusion in first-line combination regimens or for palliative treatment in heavily pretreated or elderly patients.
Sorio
R
R
Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
Tirelli
U
U
Zagonel
V
V
Carbone
A
A
Monfardini
S
S
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011379:Prognosis; D012074:Remission Induction; D012751:Sezary Syndrome / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy*; D013601:T-Lymphocytes; D013713:Teniposide / Q000008:administration & dosage / Q000627:therapeutic use*
D013713:Teniposide; D011034:Podophyllotoxin